All News

2063 articles, sorted by publication time.

Drug Discovery and Development · global

Finding Molecular Glue Targets No Longer Relies on Luck Alone: Proteome-Wide Platform Maps the CRBN Degradation Landscape

The research team connected geometric deep learning with high-throughput experiments into a single screening pipeline, identifying 43 new candidate binding proteins and revealing how adjacent zinc fingers influence degradation; however, there is still some distance between “can bind” and a safe, selective drug.

Clinical Trials · uk

From Treating Cancer to Intercepting Precancerous Lesions: Lynch Syndrome mRNA Vaccine Enters Human Trials for the First Time

An Oxford University research team has administered Moderna’s mRNA-4194 to the first participant in an attempt to prompt the immune system to eliminate precancerous cells early; at this stage, this first-in-human study is primarily assessing safety and immune responses and cannot yet demonstrate that the vaccine can prevent cancer.

Gene Editing · global

Virus-Like Particles Unlock the CRISPR Toolbox in Myeloid Immune Cells, Revealing a Potency Switch for CAR Macrophages

A new platform delivers gene knockout, base editing, and epigenetic silencing into hard-to-engineer primary monocytes, macrophages, and dendritic cells, while large-scale screening identifies TNFAIP3; the work remains at the laboratory stage, with multiple hurdles still standing between it and clinical manufacturing and safety validation.

Biomedical Engineering · global

Magnetically Controlled Microrobots Cross Gastrointestinal Barriers to Release Nanoparticle Cancer Drugs in Stages

A 550-micrometer magnetically controlled carrier first protects its drug payload with an acid-resistant coating, then releases platelet membrane-coated nanoparticles in the intestinal environment; in vitro models showed improved retention and cancer-killing effects, but animal validation and clinical application remain a long way off.

Biotechnology Industry · us

Prime Medicine Prevails in Gene-Editing Arbitration, Clearing a Preclinical Hurdle for AATD Therapy PM647

The arbitration tribunal found that PM647 falls within the development scope retained by Prime Medicine under the collaboration agreement and rejected Beam Therapeutics’ requests for damages and injunctive relief. The ruling removes a key legal obstacle, but competition between the two companies over rights to gene-editing tools is not over.